Doctor profile · Federal record

Dr. Ashley Cauthen, M.D.

Dermatology Physician (CMS: Dermatology) · Ocala, FL

  • NPI 1720254071
  • Accepts Medicare
  • MIPS 88.0 / 100 · 2023
  • 18 yrs in practice
  • Female
  • Group practice
  • No sanctions

Practice & contact

NPPES Updated May 11, 2026
Primary practice
1740 Se 18Th St Ste 1102
Ocala, FL 344715447
(352) 512-0092
fax (352) 512-0093

Credentials & registration

NPPES · NUCC
NPI registered
May 2008 — 18 yrs on file
Profile last updated
January 25, 2021
Year of graduation
2008 — 18 yrs since
Specialty taxonomy
207N00000X — NUCC code
State license (1)
Florida #ME112254

Federal sanctions & exclusions

OIG LEIE Updated May 11, 2026

No sanctions, exclusions or revocations on file

Checked against OIG LEIE on NPI 1720254071. Last verified May 11, 2026.

Medicare procedures · 2023

Top services delivered

CMS Provider Utilization
Total services
23,959
Distinct HCPCS
10
Medicare allowed
$1,659,207
HCPCS Description Services Patients Avg allowed
17003 Destruction of precancer skin growth, 2-14 growths 7,595 1,261 $6
J3245 Injection, tildrakizumab, 1 mg 3,400 11 $139
99213 Established patient office or other outpatient visit, 20-29 minutes 3,275 2,294 $90
17000 Destruction of precancer skin growth, 1 growth 2,113 1,597 $49
11102 Biopsy of related skin growth, first growth 1,372 1,097 $88
17110 Destruction of skin growth, 1-14 growths 1,138 954 $109
99214 Established patient office or other outpatient visit, 30-39 minutes 794 665 $127
11103 Biopsy of related skin growth, each additional growth 610 376 $49
96900 Application of ultraviolet light to skin 596 26 $23
99203 New patient office or other outpatient visit, 30-44 minutes 308 308 $112

In context: peer comparison

Among 8 peers in Ocala Dermatology Physician, average services per provider: 262. This provider delivers 91× the peer median.

Open Payments

Industry payments received

CMS Open Payments
All-time total
$39,637
Transactions
150
Manufacturers
15
Payer (manufacturer) Industry Txns Amount
Amgen INC. 23 $29,977.75
Galderma Laboratories, L.P. 23 $6,625.99
Sun Pharmaceutical Industries INC. 16 $521.76
Janssen Biotech, INC. 14 $423.13
E.R. Squibb & Sons, L.L.C. 20 $383.47
Regeneron Healthcare Solutions, INC. 11 $323.65
Pfizer INC. 9 $319.59
Ucb, INC. 10 $274.77
Abbvie INC. 6 $234.00
Leo Pharma INC. 4 $96.18
Arcutis Biotherapeutics, INC. 4 $76.67
Ortho Dermatologics, A Division of Bausch Health US, LLC 3 $65.63
Lilly USA, LLC 3 $62.21
Incyte Corporation 3 $61.75
Revance Therapeutics, INC. 1 $48.65

By nature of payment

Compensation for Services Other Than Consulting, Including Serving As Faculty or As A Speaker at A Venue Other Than A Continuing Education Program
$31,755
Food and Beverage
$3,980
Travel and Lodging
$3,779
Education
$92
Honoraria
$31

Medicare Part D · 2023

Top prescriptions

CMS Part D Prescriber
Total claims
883
Patients
468
Total drug cost
$422,172
Drug Type Claims Patients Total cost
Ketoconazole Generic 258 141 $6,459
Triamcinolone Acetonide Generic 170 135 $1,844
Clobetasol Propionate Generic 67 44 $3,407
Doxycycline Hyclate Generic 62 37 $1,759
Minoxidil Generic 58 18 $759
Mupirocin Generic 53 39 $681
Valacyclovir (Valacyclovir Hcl) Brand 32 24 $1,086
Otezla (Apremilast) Brand 31 0 $106,870
Cosentyx Sensoready (2 Pens) (Secukinumab) Brand 26 0 $226,911
Hydroxyzine Hcl Generic 26 0 $245

Frequently asked questions

Auto-generated from federal data
What is Dr. Ashley Cauthen's medical specialty?
Dr. Ashley Cauthen practices Dermatology Physician in Ocala, FL.
Where does Dr. Ashley Cauthen practice?
Dr. Ashley Cauthen practices at 1740 Se 18Th St Ste 1102, Ocala, FL 344715447. Office phone: 3525120092.
What is Dr. Ashley Cauthen's NPI?
Dr. Ashley Cauthen's National Provider Identifier (NPI) is 1720254071, issued by NPPES.
Does Dr. Ashley Cauthen accept Medicare assignment?
Yes. Dr. Ashley Cauthen accepts Medicare assignment, meaning Medicare-allowed amounts are accepted as full payment for covered services.
What procedures does Dr. Ashley Cauthen commonly perform?
Top Medicare-reported procedures in 2023: Destruction of precancer skin growth, 2-14 growths (HCPCS 17003); Injection, tildrakizumab, 1 mg (HCPCS J3245); Established patient office or other outpatient visit (HCPCS 99213). Source: CMS Medicare Physician & Other Practitioners file.